血漿のヨーロッパ市場2020-2122

◆英語タイトル:EUROPE BLOOD PLASMA MARKET FORECAST 2020-2028
◆商品コード:INK20MY173
◆発行会社(リサーチ会社):Inkwood Research
◆発行日:2020年4月
◆ページ数:175
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆調査対象地域:ヨーロッパ
◆販売価格オプション(消費税別)
Single UserUSD1,250 ⇒換算¥131,250見積依頼/購入/質問フォーム
Multi LicenseUSD1,500 ⇒換算¥157,500見積依頼/購入/質問フォーム
Enterprisewide PriceUSD2,000 ⇒換算¥210,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はInkwood Research社の日本における正規販売代理店です。同社発行の医療分野調査レポートに関するお問い合わせは弊社までお願い致します。
Inkwood Research社の概要はこちらでご確認いただけます。
※上記「見積依頼/購入/質問フォーム」をクリックすると弊社運営のレポート販売サイトに移動します。

【レポートの概要】

KEY FINDINGSThe Europe blood plasma market is predicted to record growth, at a CAGR of 6.39% during the forecast period. The growing geriatric population and the increasing cases of immunodeficiency diseases, are the major drivers of market growth.

MARKET INSIGHTS
The Europe blood plasma market growth assessment involves the market analysis of Russia, Germany, the United Kingdom, Italy, Belgium, Poland, France, and the rest of Europe. Germany was one of the major countries to record the highest rate of blood plasma donations through apheresis. There has been an increasing number of sports injuries that affect areas like joints or tendons. Such factors have resulted in the widespread use of blood plasma procedure due to its varied benefits. There is an increasing prevalence of osteoarthritis in Italy, leading to increased demands for blood plasma. Also, the use of polyvalent immunoglobulins that are administered through the subcutaneous route has grown over the years as a result of increasing preference for self-infusion by patients. In Russia, the rising aging population, and the resultant demand for a strong healthcare system, are set to boost market growth. The countries in the rest of Europe segment make use of blood plasma treatment for cosmetic and sports medicine treatment.

COMPETITIVE INSIGHTS
Some of the renowned companies in the market include, Grifols, Kedrion Biopharma Inc, Octapharma, Biotest AG, Cerus Corporation (Cerus), etc.
Our report offerings include:
• Explore key findings of the overall market
• Strategic breakdown of market dynamics (Drivers, Restraints, Opportunities, Challenges)
• Market forecasts for a minimum of 9 years, along with 3 years of historical data for all segments, sub-segments, and regions
• Market Segmentation cater to a thorough assessment of key segments with their market estimations
• Geographical Analysis: Assessments of the mentioned regions and country-level segments with their market share
• Key analytics: Porter’s Five Forces Analysis, Vendor Landscape, Opportunity Matrix, Key Buying Criteria, etc.
• Competitive landscape is the theoretical explanation of the key companies based on factors, market share, etc.
• Company profiling: A detailed company overview, product/services offered, SCOT analysis, and recent strategic developments

【レポートの目次】

1. RESEARCH SCOPE & METHODOLOGY
1.1. STUDY OBJECTIVES
1.2. SCOPE OF STUDY
1.3. METHODOLOGY
1.4. ASSUMPTIONS & LIMITATIONS
2. EXECUTIVE SUMMARY
2.1. MARKET SIZE & ESTIMATES
2.2. MARKET OVERVIEW
3. MARKET DYNAMICS
3.1. PARENT MARKET ANALYSIS: BLOOD MARKET
3.2. MARKET DEFINITION
3.3. KEY DRIVERS
3.3.1. WIDESPREAD ACCEPTANCE OF IMMUNOGLOBULIN-BASED THERAPIES
3.3.2. GROWING USAGE OF ALBUMIN IN OTHER THERAPEUTIC AREAS
3.3.3. GROWING GERIATRIC POPULATION IN EUROPE
3.3.4. SPREAD OF COVID-19 IN EUROPEAN REGION
3.3.5. INCREASE IN THE PATIENT POOL FOR HEMOPHILIA TREATMENT
3.3.6. GROWTH IN AWARENESS ABOUT BLOOD AND PLASMA DONATION
3.3.7. RISE IN OCCURRENCE OF SPORTS INJURIES
3.4. KEY RESTRAINTS
3.4.1. HIGH COST OF BLOOD PLASMA TREATMENTS
3.4.2. INCREASING USAGE OF RECOMBINANT PLASMA PRODUCTS IN THERAPEUTIC TREATMENTS
3.4.3. ADVERSE REACTIONS ASSOCIATED WITH POST-TRANSFUSION
3.4.4. STRINGENT REGULATIONS
4. KEY ANALYTICS
4.1. KEY INVESTMENT INSIGHTS
4.2. PORTER’S FIVE FORCE ANALYSIS
4.2.1. BUYER POWER
4.2.2. SUPPLIER POWER
4.2.3. SUBSTITUTION
4.2.4. NEW ENTRANTS
4.2.5. INDUSTRY RIVALRY
4.3. OPPORTUNITY MATRIX
4.4. VENDOR LANDSCAPE
4.5. PLASMA THERAPEUTICS REGULATION
4.6. MARKET TRENDS
4.7. CLINICAL GUIDELINES
5. MARKET BY BLOOD PLASMA DERIVATIVES
5.1. IMMUNOGLOBULIN
5.1.1. INTRAVENOUS IMMUNOGLOBULIN
5.1.2. SUBCUTANEOUS IMMUNOGLOBULIN
5.1.3. OTHER IMMUNOGLOBULIN TYPE
5.2. ALBUMIN
5.3. HYPERIMMUNE
5.4. COAGULATION FACTOR CONCENTRATES
5.5. OTHER PLASMA FRACTIONATION PRODUCTS
6. MARKET BY THERAPEUTIC INDICATION
6.1. NEUROLOGY
6.2. IMMUNOLOGY
6.3. ONCOLOGY
6.4. TRANSPLANTATION
6.5. HEMATOLOGY
6.6. RHEUMATOLOGY
6.7. PULMONOLOGY
6.8. OTHER THERAPEUTIC INDICATION
7. MARKET BY DISORDER
7.1. IMMUNODEFICIENCY DISEASES
7.2. HYPOGAMMAGLOBULINEMIA
7.3. HEMOPHILIA
7.4. VON WILLEBRAND DISEASE (VWD)
7.5. OTHER DISORDER
8. MARKET BY END-USER
8.1. HOSPITALS AND CLINICS
8.2. RESEARCH LABORATORIES
8.3. ACADEMIC INSTITUTIONS
9. GEOGRAPHICAL ANALYSIS
9.1. EUROPE
9.1.1. UNITED KINGDOM
9.1.2. GERMANY
9.1.3. FRANCE
9.1.4. ITALY
9.1.5. RUSSIA
9.1.6. BELGIUM
9.1.7. POLAND
9.1.8. REST OF EUROPE
10. COMPANY PROFILES
10.1. ADMA BIOLOGICS
10.2. ARTHREX
10.3. BIO PRODUCTS LABORATORY
10.4. BAXTER INTERNATIONAL
10.5. BIOTEST AG
10.6. CERUS CORPORATION (CERUS)
10.7. CHINA BIOLOGIC PRODUCTS
10.8. CSL LIMITED
10.9. FUSION HEALTH CARE
10.10. GREEN CROSS HOLDINGS CORPORATION
10.11. GRIFOLS
10.12. LFB
10.13. OCTAPHARMA
10.14. TAKEDA PHARMACEUTICAL COMPANY
10.15. KEDRION BIOPHARMA INC



【免責事項】
https://www.marketreport.jp/reports-disclaimer

★医療情報レポート[血漿のヨーロッパ市場2020-2122]についてメールでお問い合わせはこちら



◆H&Iグローバルリサーチ株式会社のお客様(例)◆